{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 189,
  "pageCount": 239,
  "prevPage": 188,
  "nextPage": 190,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses highlighted text to emphasize key negative sentiment regarding Nevro's customer loyalty and future market position.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/189",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-189",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Nevro faces an impending, disruptive competitive threat within 6 to 12 months: Saluda",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b346-f6e68a80bab1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "14. Unknown to most investors, Nevro faces an impending, disruptive competitive threat within 6 to 12 months: Saluda Interviews with competitors – at the executive, territory manager, and sales rep level – indicated that they expect Saluda to take “a lot of share.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f693fa6c-8004-41f6-ae54-2c202c35185b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.76
      },
      "kind": "quote",
      "text": "When Saluda comes into play, I think the market is going to shift and take a look at them.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "195e419c-724a-49ac-bcc3-fe780fd5ae71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.52
      },
      "kind": "quote",
      "text": "Saluda will absolutely take share. It’s totally different than anything out there. Doctors will absolutely want to go to it. It’ll be like having a Nevro launch all over again. They’ll take a lot of share.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "844f2def-d89a-4461-a0f9-39a10ea42b6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.66
      },
      "kind": "quote",
      "text": "I think Saluda will have an impact. I think there will be a splash.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92b6bc05-6ea8-48cf-968f-8ce9d0a96ed1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.31
      },
      "kind": "quote",
      "text": "Omnia is a bump for a couple of quarters. Once Saluda is launched... you’re going to see the early Omnia doctors leave Nevro to try Saluda... Nevro’s customer base are people that are fickle.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db0c5b2e-1a85-4a20-9770-db7f09d403c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Omnia is a bump for a couple of quarters. Once Saluda is launched, whenever that may be in 6 to 12 months,, you're going to see the early Omnia doctors leave Nevro to try Saluda. So, I think if anyone gets impacted by Saluda, it's going to be Nevro more than any of the other three big players. Nevro when it first came out got the early adopter types of doctors, and Saluda will make an impact with those doctors that try new technologies within the first 6-12 months. Correct, I'm saying that Nevro's customer base are people that are fickle. — Former Nevro district sales manager, now playing similar role at a key competitor; Saluda will absolutely take share. It's totally different than anything out there. Doctors will absolutely want to go to it. It'll be like having a Nevro launch all over again. They'll take a lot of share. It's a novel approach to pain. — Medtronic territory manager for a key multi-state region; I think Saluda will have an impact. I think there will be a splash. — Medtronic territory manager for one of their largest regions; When Saluda comes into play, I think the market is going to shift and take a look at them. — Longtime C-level executive in the SCS space",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b346-f83f29343f8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d83e05d-da65-4a49-9c46-3ce1acb50873",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1f425bf-d4d9-46d2-8a5e-cd51b6992224",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "e13818c2-e5e1-4452-807a-9e3793d01ada",
      "evidence": "Citing industry experts and competitors to validate the thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}